Last reviewed · How we verify
Arbidol
At a glance
| Generic name | Arbidol |
|---|---|
| Also known as | Arbidol Hydrochloride, The basic treatment used by the investigator was based on the condition of the patient |
| Sponsor | Zheng Liu |
| Target | Hemagglutinin [Cleaved into: Hemagglutinin HA1 chain; Hemagglutinin HA2 chain] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Influenza
Common side effects
Key clinical trials
- The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. (PHASE4)
- Severe Influenza Trial of ARbidol (PHASE3)
- Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis (NA)
- Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection
- Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19 (PHASE2, PHASE3)
- Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19) (NA)
- Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus (PHASE4)
- The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arbidol CI brief — competitive landscape report
- Arbidol updates RSS · CI watch RSS
- Zheng Liu portfolio CI